Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

671 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.
Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, Katsuramaki T, Yasoshima T, Sasaki K, Mizushima Y, Minamida H, Kimura H, Akiyama M, Hirohashi Y, Asanuma H, Tamura Y, Shimozawa K, Sato N, Hirata K. Tsuruma T, et al. Among authors: asanuma h. J Transl Med. 2004 Jun 13;2(1):19. doi: 10.1186/1479-5876-2-19. J Transl Med. 2004. PMID: 15193151 Free PMC article.
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.
Tsuruma T, Iwayama Y, Ohmura T, Katsuramaki T, Hata F, Furuhata T, Yamaguchi K, Kimura Y, Torigoe T, Toyota N, Yagihashi A, Hirohashi Y, Asanuma H, Shimozawa K, Okazaki M, Mizushima Y, Nomura N, Sato N, Hirata K. Tsuruma T, et al. Among authors: asanuma h. J Transl Med. 2008 May 10;6:24. doi: 10.1186/1479-5876-6-24. J Transl Med. 2008. PMID: 18471305 Free PMC article. Clinical Trial.
Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor.
Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T, Sato N. Tsukahara T, et al. Among authors: asanuma h. Cancer Res. 2004 Aug 1;64(15):5442-8. doi: 10.1158/0008-5472.CAN-04-0522. Cancer Res. 2004. PMID: 15289353
Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5.
Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N. Tsukahara T, et al. Among authors: asanuma h. Cancer Sci. 2006 Dec;97(12):1374-80. doi: 10.1111/j.1349-7006.2006.00317.x. Epub 2006 Sep 21. Cancer Sci. 2006. PMID: 16995877 Free PMC article.
Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, Asanuma H, Takahashi A, Michifuri Y, Nakamori K, Nagai I, Sato N, Hiratsuka H. Miyazaki A, et al. Among authors: asanuma h. Cancer Sci. 2011 Feb;102(2):324-9. doi: 10.1111/j.1349-7006.2010.01789.x. Epub 2010 Dec 10. Cancer Sci. 2011. PMID: 21143701 Free article. Clinical Trial.
Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.
Tsukahara T, Emori M, Murata K, Hirano T, Muroi N, Kyono M, Toji S, Watanabe K, Torigoe T, Kochin V, Asanuma H, Matsumiya H, Yamashita K, Himi T, Ichimiya S, Wada T, Yamashita T, Hasegawa T, Sato N. Tsukahara T, et al. Among authors: asanuma h. J Biol Chem. 2014 Aug 8;289(32):22035-47. doi: 10.1074/jbc.M114.568725. Epub 2014 Jun 24. J Biol Chem. 2014. PMID: 24962571 Free PMC article.
671 results